PYC's Second Lead Program Being Developed for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) Caused by Mutations in the OPA1 Gene, for Which There Are Currently No Approved Treatments or Drugs in Clinical Development
PYC's Differentiated PPMO Technology Results in Effective Delivery to Target Cells in the Retina in Vivo and Greater Than 1.5-Fold Upregulation of the Target OPA1 Protein and Correction of Major Functional Deficits in Patient-Derived Cells
PR Newswire
SAN DIEGO and PERTH, Australia, June 29, 2021